类似葡萄糖类-1受体激动剂:一种用于药物使用障碍的新征兆?
Farage Ftiha1, Joey Ftiha2, Manish A Parikh1,3
1From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.
Cardiology in review
|December 16, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 通过减少多巴胺系统活性,在治疗酒精和物质使用障碍方面表现有前途. 塞马格卢提德和利拉格卢提德特别减少了相关的住院治疗,优于其他治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是药物使用障碍的新兴治疗方法.
- GLP-1RAs向G蛋白结合受体,影响像多巴胺这样的神经递质系统.
- 这些受体广泛存在,在大脑和肠道中度很高.
研究的目的:
- 审查支持GLP-1RAs在管理酒精和相关物质使用障碍 (ASUD) 的证据.
- 探索GLP-1RAs可能影响ASUD的机制.
- 为了比较不同GLP-1RA和标准药物疗法的疗效.
主要方法:
- 对ASUD中GLP-1RA使用的观察文献的综述.
- 对研究GLP-1RA对多巴胺奖励系统的影响的研究分析.
- 与各种GLP-1RA和标准治疗相关的住院率的比较.
主要成果:
- GLP-1RAs对与ASUD相关的住院治疗具有缓解作用.
- 与其他GLP-1RA相比,塞马格卢提德和利拉格卢提德在ASUD相关住院病例的减少更大.
- 这些发现表明,与现有的ASUD药物疗法相比,这种药物疗法具有潜在的益处.
结论:
- GLP-1RAs代表了对酒精和物质使用障碍的有希望的治疗途径.
- 具体的药物,如塞马格卢提德和利拉格卢提德,需要进一步研究ASUD治疗.
- 该机制涉及对大脑多巴胺奖励通路的调节.
相关概念视频
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
Substance Use Disorders Affecting Sleep
366
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
366
Drug Abuse and Addiction: Pharmacological Phenomena
1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562


